Cargando…

Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans

Atrial fibrillation (AF) is the most persistent arrhythmia today, with its prevalence increasing exponentially with the rising age of the population. Particularly at elevated heart rates, a functional abnormality known as cardiac alternans can occur prior to the onset of lethal arrhythmias. Cardiac...

Descripción completa

Detalles Bibliográficos
Autores principales: Muthavarapu, Neha, Mohan, Anmol, Manga, Sharanya, Sharma, Palak, Bhanushali, Aditi Kishor, Yadav, Ashima, Damani, Devanshi Narendra, Jais, Pierre, Walton, Richard D., Arunachalam, Shivaram P., Kulkarni, Kanchan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959422/
https://www.ncbi.nlm.nih.gov/pubmed/36826532
http://dx.doi.org/10.3390/jcdd10020036
_version_ 1784895272581595136
author Muthavarapu, Neha
Mohan, Anmol
Manga, Sharanya
Sharma, Palak
Bhanushali, Aditi Kishor
Yadav, Ashima
Damani, Devanshi Narendra
Jais, Pierre
Walton, Richard D.
Arunachalam, Shivaram P.
Kulkarni, Kanchan
author_facet Muthavarapu, Neha
Mohan, Anmol
Manga, Sharanya
Sharma, Palak
Bhanushali, Aditi Kishor
Yadav, Ashima
Damani, Devanshi Narendra
Jais, Pierre
Walton, Richard D.
Arunachalam, Shivaram P.
Kulkarni, Kanchan
author_sort Muthavarapu, Neha
collection PubMed
description Atrial fibrillation (AF) is the most persistent arrhythmia today, with its prevalence increasing exponentially with the rising age of the population. Particularly at elevated heart rates, a functional abnormality known as cardiac alternans can occur prior to the onset of lethal arrhythmias. Cardiac alternans are a beat-to-beat oscillation of electrical activity and the force of cardiac muscle contraction. Extensive evidence has demonstrated that microvolt T-wave alternans can predict ventricular fibrillation vulnerability and the risk of sudden cardiac death. The majority of our knowledge of the mechanisms of alternans stems from studies of ventricular electrophysiology, although recent studies offer promising evidence of the potential of atrial alternans in predicting the risk of AF. Exciting preclinical and clinical studies have demonstrated a link between atrial alternans and the onset of atrial tachyarrhythmias. Here, we provide a comprehensive review of the clinical utility of atrial alternans in identifying the risk and guiding treatment of AF.
format Online
Article
Text
id pubmed-9959422
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99594222023-02-26 Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans Muthavarapu, Neha Mohan, Anmol Manga, Sharanya Sharma, Palak Bhanushali, Aditi Kishor Yadav, Ashima Damani, Devanshi Narendra Jais, Pierre Walton, Richard D. Arunachalam, Shivaram P. Kulkarni, Kanchan J Cardiovasc Dev Dis Review Atrial fibrillation (AF) is the most persistent arrhythmia today, with its prevalence increasing exponentially with the rising age of the population. Particularly at elevated heart rates, a functional abnormality known as cardiac alternans can occur prior to the onset of lethal arrhythmias. Cardiac alternans are a beat-to-beat oscillation of electrical activity and the force of cardiac muscle contraction. Extensive evidence has demonstrated that microvolt T-wave alternans can predict ventricular fibrillation vulnerability and the risk of sudden cardiac death. The majority of our knowledge of the mechanisms of alternans stems from studies of ventricular electrophysiology, although recent studies offer promising evidence of the potential of atrial alternans in predicting the risk of AF. Exciting preclinical and clinical studies have demonstrated a link between atrial alternans and the onset of atrial tachyarrhythmias. Here, we provide a comprehensive review of the clinical utility of atrial alternans in identifying the risk and guiding treatment of AF. MDPI 2023-01-20 /pmc/articles/PMC9959422/ /pubmed/36826532 http://dx.doi.org/10.3390/jcdd10020036 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Muthavarapu, Neha
Mohan, Anmol
Manga, Sharanya
Sharma, Palak
Bhanushali, Aditi Kishor
Yadav, Ashima
Damani, Devanshi Narendra
Jais, Pierre
Walton, Richard D.
Arunachalam, Shivaram P.
Kulkarni, Kanchan
Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans
title Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans
title_full Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans
title_fullStr Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans
title_full_unstemmed Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans
title_short Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans
title_sort targeted atrial fibrillation therapy and risk stratification using atrial alternans
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959422/
https://www.ncbi.nlm.nih.gov/pubmed/36826532
http://dx.doi.org/10.3390/jcdd10020036
work_keys_str_mv AT muthavarapuneha targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans
AT mohananmol targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans
AT mangasharanya targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans
AT sharmapalak targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans
AT bhanushaliaditikishor targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans
AT yadavashima targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans
AT damanidevanshinarendra targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans
AT jaispierre targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans
AT waltonrichardd targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans
AT arunachalamshivaramp targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans
AT kulkarnikanchan targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans